Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Phase 3

Completed

• Conditions: Mydriasis
• Interventions: Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE); Drug: Tropicamide 1% ophthalmic solution (TR); Drug: Phenylephrine 2.5% ophthalmic solution (PE)

• Registration Number: NCT03751631
• Lead Sponsor: Eyenovia Inc.

Brief Summary

This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PE) vs. phenylephrine (PE) alone and tropicamide (TR) alone. Participants attended 3 visits. At each visit, after baseline measurements, 1 of the 3 drugs was administered to both eyes, then pupil dilation and safety assessments were performed at specific time intervals.

Detailed Description

Volunteer participants were screened for study eligibility during a Screening Visit and enrolled after signing the study-specific informed consent form. Subjects meeting all inclusion/exclusion criteria were scheduled for 3 treatment visits, which were at least 2 days, but no more than 7 days apart. At each treatment visit, baseline measurements were taken, then 1 of the 3 study drugs was administered to both eyes (each participant's drug administration sequence was randomly determined). Afterwards, efficacy and safety assessments were performed at 20, 35, 50, 65, 80, 120, and 180 minutes.

Study Timeline

• Study First Submitted: 2018-11-14
• Study Start: 2018-11-15
• Study First Submitted QC: 2018-11-21
• Study First Posted: 2018-11-23
• Primary Completion: 2019-01-11
• Study Completion: 2019-01-11
• Disposition First Submitted: 2020-01-31
• Status Verified: 2022-01
• Results First Submitted: 2022-01-27
• Results First Submitted QC: 2022-03-16
• Disposition First Submitted QC: 2022-03-16
• Last Update Submitted: 2022-03-16
• Results First Posted: 2022-03-18
• Disposition First Posted: 2022-03-18
• Last Update Posted: 2022-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Ability to provide written consent and return for all study visits
• Photopic pupil diameter <= 3.5 mm in each eye

Exclusion Criteria

• Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride
• History of benign prostatic hyperplasia
• Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant, anticonvulsant, or cholinergic drug
• History of closed-angle glaucoma
• Anatomically narrow anterior chamber angles
• Ocular surgery or laser treatment of any kind
• History of chronic or acute uveitis
• History of traumatic iritis or hyphema
• History of traumatic mydriasis or angle recession
• History of heterochromia
• Irregularly-shaped pupil secondary to ocular trauma or congenital defect.
• History of neurogenic pupil disorder
• History of anterior chamber intraocular lens (IOL) or iris-fixated IOL
• History of iris surgery, iris atrophy, or iris-cornea apposition/touch
• Unwilling or unable to discontinue use of contact lenses at treatment visits.
• Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye disease managed using artificial tears.
• Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment and/or follow-up
• Pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1-TR, 2-TR/PE, 3-PE	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-TR, 3-PE	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR, 2-PE, 3-TR/PE	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR/PE, 3-TR	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-PE, 3-TR	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR, 2-PE, 3-TR/PE	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR/PE, 3-TR	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR, 3-TR/PE	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-TR, 3-PE	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-PE, 3-TR	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR, 2-TR/PE, 3-PE	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR, 2-PE, 3-TR/PE	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR, 3-TR/PE	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR, 2-TR/PE, 3-PE	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-PE, 3-TR	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR/PE, 3-TR	Phenylephrine 2.5% ophthalmic solution (PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-PE, 2-TR, 3-TR/PE	Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
1-TR/PE, 2-TR, 3-PE	Tropicamide 1% ophthalmic solution (TR)	Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.

Primary Outcome Measures

Name	Time	Method
Change in Pupil Diameter From Baseline	35 minutes after initial dose	Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.; Pupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome.

Trial Locations

Locations (1)

WCCT; 🇺🇸 Cypress, California, United States